Whole genome sequencing-based copy number variations reveal novel pathways and targets in Alzheimer’s disease.

A few copy number variations (CNVs) have been reported for Alzheimer’s disease (AD). However, there is a lack of a systematic investigation of CNVs in AD based on whole genome sequencing (WGS) data.